Truist Financial Corp Has $336,000 Holdings in Repligen Co. (NASDAQ:RGEN)

Truist Financial Corp lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 20.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,667 shares of the biotechnology company’s stock after selling 680 shares during the period. Truist Financial Corp’s holdings in Repligen were worth $336,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. CWM LLC grew its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after buying an additional 89 shares in the last quarter. Diversified Trust Co lifted its stake in shares of Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after acquiring an additional 106 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its holdings in shares of Repligen by 6.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 125 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity

In related news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on RGEN shares. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and reduced their price target for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. UBS Group dropped their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $146.95 on Friday. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The stock’s 50 day moving average is $145.39 and its 200-day moving average is $148.49. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.23 billion, a price-to-earnings ratio of -3,672.83, a PEG ratio of 4.13 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business’s revenue was down 3.2% on a year-over-year basis. During the same period last year, the company earned $0.53 earnings per share. Sell-side analysts forecast that Repligen Co. will post 1.45 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.